Role of Oral Iron Supplementation in Treatment of Anemia Secondary to Acute Nonvariceal Upper Gastrointestinal Bleeding: A Randomized Controlled Trial
- Conditions
- non variceal upper gastrointestinal bleedingoral iron supplement, anemia, non variceal upper gastrointestinal bleeding
- Registration Number
- TCTR20190225002
- Lead Sponsor
- Hatyai Hospital Foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 168
1. non variceal upper gastrointestinal bleeding who admited in hospital
2. age between 18-75 years
3. who was diagnosed with anemia secondary to UGIB on the day of inclusion (Anemia was defined according to the definitions of the World Health Organization (WHO): hemoglobin level lower than 12 g/dL for women and 13 g/dL for men)
(1) pregnant or nursing mothers
(2) pathologies that could influence anemia progression (including chronic renal failure, decompensated cirrhosis, cancer, presence of systemic inflammatory response syndrome [SIRS] or sepsis)
(3) history of overt UGIB within 3 months prior to inclusion
(4) previous iron supplementation intake within 3 months
(5) history of chronic anemia or treatment of erythropoietin
(6) contraindication of iron use (e.g., hemochromatosis, thalassemia major, and history of allergy to oral iron medicine)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum hemoglobin level 6 week after upper gastrointestinal bleeding g/d
- Secondary Outcome Measures
Name Time Method serum iron 6 week after upper gastrointestinal bleeding microgram/dL,TIBC 6 week after upper gastrointestinal bleeding microgram/dL,Serum ferritin 6 week after upper gastrointestinal bleeding nanogram/dL,adverse drugs reaction of iron supplement 6 week after upper gastrointestinal bleeding times